

Colorectal Cancer in Latin America: Quick Comment

Authors: Veronica Salais Michaus • Erika Ruiz-Garcia

Correspondence: betzabe100@yahoo.com.mx

Corresponding author: Erika Ruiz-Garcia

Affiliation: Gastrointestinal Oncology Department and Traslational Medicine
Laboratory, Instituto Nacional de Cancerologia, Mexico

Published: July 21, 2025



doi.org/10.69690/ODMJ-018-0425-4320



Colorectal Cancer in Latin America: Quick Comment

Author: Veronica Salais Michaus • Erika Ruiz-Garcia

Published: July 21, 2025

INTRODUCTION

Within the framework of Colorectal Cancer Awareness Month, much attention is given to a cancer that is potentially preventable. But what is the status of gastrointestinal cancers in Latin America (LATAM), specifically colorectal cancer?

Meanwhile, real-world Latin American oncologists focus their primary efforts on breaking barriers to access cost-effective therapies for our population, and patients navigate the long and complex journey to reach cancer care centers. Considering that LATAM includes a large number of countries with heterogeneous populations and health systems, we made efforts to summarize the available literature data in terms of epidemiology, risk factors, type and nature of symptoms, development stages, available test and treatments of colorectal cancer with a bibliographic search conducted in the PubMed/MEDLINE, Google Scholar databases from 2014-2024.

EPIDEMIOLOGY IN LATIN AMERICA

In Latin America, cancer incidence and mortality have been rising over the past decade. Colorectal cancer (CRC) ranks third in incidence and second

in mortality in the region, according to the Global Cancer Observatory 2022¹. In Mexico, for example, it is the leading cause of cancer-related death.² But even more, CRC is the second-most common malignant neoplasm among Latinos in the United States.

The population in Latin America and the Caribbean (LAC) has doubled in the past fifty years. Combined with increased life expectancy and other contributing factors, this has led to an exponential rise in cancer incidence. As Piñeros et al.³ highlighted, colorectal cancer incidence is increasing, especially in low-income countries, while in the United States, mortality rates are decreasing significantly for both sexes. Specifically related to CRC in LATAM, it is predicted to increase by 60% by 2030. In contrast, global projections to 2035 predict a decrease in colorectal cancer mortality in high-income countries, particularly in Northern and Western Europe⁴. However, between 1990 and 2019, age-adjusted colorectal cancer mortality in Latin America rose by 20.56%⁵. These trends vary greatly between countries, reflecting healthcare inequalities that remain a major contributor to cancer-related mortality in the region.

A significant difference in cancer presentation is also observed. In high-income countries,

approximately 71% of patients are diagnosed at early or locally advanced stages with curative intent as the main objective of treatment⁶. By contrast, in Mexico, 60% of cancers. Colon cancer is among the top five cancers that are diagnosed at advanced stages⁷, where treatment is so complex and expensive, contributing to higher mortality.

OPPORTUNITIES AND BARRIERS IN LATIN AMERICA

After receiving a diagnosis of colorectal cancer, patients face additional challenges related to treatment chronicity, cost, and access. Randomized clinical trials have shown survival benefits with the addition of targeted biologics to chemotherapy in metastatic colorectal cancer (mCRC), based on diagnostic, predictive, or prognostic markers⁸. According to literature mutations in KRAS are present in ~40% of CRC cases (G12C in ~3%)⁹, BRAF mutations in ~10% (95% are V600E)¹⁰, HER2 amplification in ~6%¹¹, and dMMR/MSI-H in 10–20% of CRCs but only ~3.5% of mCRCs¹². But even the cornerstone of systemic therapy is fluoropyrimidine-based chemotherapy in combination with oxaliplatin and/or irinotecan, with or without anti-VEGF or anti-EGFR monoclonal antibodies, and nowadays the immunotherapy, was it is evident is that neither health infrastructure nor access to health care for all cancer patients is available in LATAM due to the fragmented and complex health systems in the region¹³.

Without doubt, LATAM countries are making various efforts trying to change the prognosis of mCRC patients; to cite just a few, they have established consensus guidelines from Central America and the Caribbean that emphasize additional approaches for oligometastatic disease, such as synchronous liver and lung metastases, and in parallel others have shown the impact on overall survival and quality of life of a good selection therapy, even amid the limitations of the region^{14,15}.

As previously mentioned, systemic therapy for chemo-refractory mCRC remains an unmet need in LATAM. Despite significant advances in cancer therapeutics, access to standard-of-care treatments continues to be uneven across the region. One potential strategy to address this

gap is through the increased participation of Latin American patients in clinical trials. However, in recent years, only 3.64% of oncology clinical trials have been conducted in LATAM¹⁶, with even lower representation in early-phase studies. Disparities are especially evident in tumor types such as prostate, thyroid, cervical, leukemia, and colorectal cancers. While countries like Argentina and Mexico demonstrate relatively higher trial participation, others, such as Brazil, remain underrepresented in proportion to their cancer burden. Multiple factors contribute to this situation, among which the variability in clinical trial approval timelines plays a key role, ranging from 2.8 to 9 months depending on the country¹⁶.

Real-world evidence is increasingly important in oncology, as it complements clinical trial data by reflecting how treatments perform in everyday clinical settings. It includes diverse patient populations and helps inform regulatory decisions, improve access to therapies, and address healthcare disparities, especially relevant in regions like Latin America. In Brazil, most mCRC patients are treated by re-exposing them to prior regimens (85% in third-line, 71% in fourth-line), and in fewer cases, regorafenib is used¹⁷. In contrast, real-world data from Argentina, involving BRAF V600E-mCRC patients, revealed significant variability in treatment and limited access to targeted therapies¹⁸.

What is the status of biomarkers in colorectal cancer? In several Latin American countries, there is trained personnel and infrastructure in place for the analysis of key genes involved in the management of colorectal cancer. However, one of the main challenges is the high cost of laboratory reagents, which must often be imported from the United States or Europe. Additionally, the limited availability of targeted therapies may contribute to low demand for molecular testing among healthcare providers, which can further increase the cost per test. Nonetheless, access has improved in recent years, partly due to support from pharmaceutical companies, leading to a noticeable increase in the use of RAS, BRAF, and MSI testing¹⁹. Regarding next-generation sequencing (NGS), or circulating tumor DNA (ctDNA), the costs in Latin America can be up to ten times higher than those in high-income countries. In this context, and to address this situation, specifically in Mexico, the Instituto Nacional de Cancerología is establishing the

National Genotyping Center for Cancer, aiming to identify both somatic and germline alterations across various tumor types.

On the other hand, an even greater challenge lies in the considerable ethnic diversity across Latin America, which adds complexity on multiple levels, not only in terms of treatment response but also about pharmacogenetics. For instance, while dihydropyrimidine dehydrogenase deficiency (DPYD) testing is mandatory in many European countries, in Latin America it remains optional. Moreover, most commercially available DPYD tests are based on single-nucleotide polymorphisms (SNPs) identified in Caucasian populations. As a result, screening for dihydropyrimidine dehydrogenase deficiency and associated DPYD variants is not a “one-size-fits-all” approach. It is essential to account for ethnic ancestry and the genetic diversity that influences both DPD activity and the prevalence of pathogenic DPYD variants in non-Caucasian populations²⁰.

Another major challenge in Latin America (LATAM) is the implementation and sustainability of colorectal cancer (CRC) screening programs. A recently published systematic review and meta-analysis, which included 17 studies conducted in upper-middle- and high-income countries in the

region, reported a pooled participation rate of 85.8% in fecal immunochemical test (FIT)-based screening programs²¹. In contrast, a qualitative study conducted in a low-income urban community in Mexico City identified multiple barriers to CRC screening. These included limited public awareness, fear of a cancer diagnosis, logistical difficulties, and insufficient training among healthcare providers²². What we have learned is that successful screening programs must incorporate strategies such as providing free or low-cost testing, training primary care personnel, and delivering culturally sensitive education that avoids fear-based messaging. Education remains a cornerstone for improving participation and outcomes in CRC screening across LATAM.

Given all this information, we can highlight a practical point of view to make efforts and improve outcomes for patients with CRC. Suggesting as a priority to allocate resources for colorectal cancer screening programs, raise awareness about colorectal cancer, its risk factors, and the importance of screening, and identify and collaborate with community organizations. Table 1 summarizes the key points of the current scenario in Latin America.

Table 1. Current scenario in Latin America.

Country	Incidence per 100.000 (GLOBOCAN 2022) ²³	Mortality per 10,000 (GLOBOCAN 2022) ²³	Stage at diagnosis
Uruguay ²⁴	21	11.2	54% stage IV
Puerto Rico ²⁵	19.5	10.1	15.4% stage IV
Argentina ⁵	19	10.4	22% stage IV
Paraguay ²⁶	16.3	7.2	30% stage IV
Cuba ²⁷	15.2	9.4	27.3% stage IV
Chile ²⁸	15.2	9.4	Estimated 23% stage IV
Colombia ²⁹	11.2	5.8	Estimated 22.1% stage IV
Panama ³⁰	10.9	5.0	Estimated 22% stage IV
Brazil ³¹	10.9	5.7	27.7% stage IV
Costa Rica ³²	9.5	6.3	18.9% stage IV
Peru ³³	8.6	4.4	9.1% stage IV
Ecuador ³⁴	8.6	4.4	35% stage IV
Mexico ³⁵	8.1	4.4	33% stage IV

CONCLUSIONS

Colorectal cancer is a growing public health concern in Latin America, marked by rising incidence, late-stage diagnoses, and limited access to standard treatments. Despite having trained personnel and diagnostic infrastructure, high costs and fragmented healthcare systems hinder widespread use of molecular testing and targeted therapies. Real-world evidence highlights disparities in treatment patterns and access across countries. Participation in clinical trials remains low, particularly in early-phase studies, further limiting therapeutic options. Ethnic diversity adds complexity not only to treatment responses but also regarding testing, underscoring the need for tailored approaches. Strengthening health systems, improving biomarker access, and fostering inclusion in clinical research are urgent priorities. Targeted regional strategies are essential to address these gaps and improve outcomes in the mCRC in the LATAM region.

REFERENCES

1. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*. 2024 May-Jun;74(3):229-63. doi: 10.3322/caac.21834. Epub 2024 Apr 4.

2. Gobierno de México. 131. Necesario modificar estilos de vida para evitar desarrollo de cáncer colorrectal: INCan. Secretaría de Salud. Available from: <https://www.gob.mx/salud/prensa/131-necesario-modificar-estilos-de-vida-para-evitar-desarrollo-de-cancer-colorrectal-incan?idiom=es>. Accessed 9 Jul 2025.

3. Piñeros M, Laversanne M, Barrios E, Cancela MC, de Vries E, Pardo C, et al. An updated profile of the cancer burden, patterns and trends in Latin America and the Caribbean. *Lancet Reg Health Am*. 2022 Sep;13:None. doi: 10.1016/j.lana.2022.100294.

4. Araghi M, Soerjomataram I, Jenkins M, Brierley J, Morris E, Bray F, et al. Global trends in colorectal cancer mortality: projections to the year 2035. *Int J Cancer*. 2019 Jun 15;144(12):2992-3000. doi: 10.1002/ijc.32055. Epub 2019 Jan 8.

5. Muzi CD, Banegas MP, Guimarães RM, et al. Colorectal cancer disparities in Latin America: Mortality trends 1990-2019 and a paradox association with human development. *PLoS One*. 2023 Aug 25;18(8):e0289675. doi: 10.1371/journal.pone.0289675.

6. SEER Cancer Statistics. Colorectal cancer. National Cancer Institute. Available from: <https://seer.cancer.gov/statfacts/html/colorect.html>. Accessed 9 Jul 2025.

7. Reynoso-Noverón N, Meneses-García A, Erazo-Valle A, Escudero-de Los Ríos P, Kuri-Morales PA, Mohar-Betancourt A. Challenges in the development and implementation of the National Comprehensive Cancer Control Program in Mexico. *Salud Publica Mex*. 2016 Apr;58(2):325-33. doi: 10.21149/spm.v58i2.7804.

8. Modest DP, Pant S, Sartore-Bianchi A. Treatment sequencing in metastatic colorectal cancer. *Eur J Cancer*. 2019 Mar;109:70-83. doi: 10.1016/j.ejca.2018.12.019. Epub 2019 Jan 25.

9. Ji J, Wang C, Fakih M. Targeting KRASG12C-mutated advanced colorectal cancer: research and clinical developments. *Onco Targets Ther*. 2022 Jul 7;15:747-56. doi: 10.2147/OTT.S340392.

10. Tabernero J, Ros J, Élez E. The evolving treatment landscape in BRAF-V600E-mutated metastatic colorectal cancer. *Am Soc Clin Oncol Educ Book*. 2022 Apr;42:1-10. doi: 10.1200/EDBK_349561.

11. Seo AN, Kwak Y, Kim DW, Kang SB, Choe G, Kim WH, et al. HER2 status in colorectal cancer: its clinical significance and the relationship between HER2 gene amplification and expression. *PLoS One*. 2014 May 30;9(5):e98528. doi: 10.1371/journal.pone.0098528.

12. Koopman M, Kortman GA, Mekenkamp L, Ligtenberg MJ, Hoogerbrugge N, Antonini NF, et al. Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. *Br J Cancer*. 2009 Jan 27;100(2):266-73. doi: 10.1038/sj.bjc.6604867.

13. Di Mauro A, Santorsola M, Savarese G, Sirica R, Ianniello M, Cossu AM, et al. High tumor mutational burden assessed through next-generation sequencing predicts favorable survival in microsatellite stable metastatic colon cancer patients. *J Transl Med*. 2024 Dec 5;22(1):1107. doi: 10.1186/s12967-024-05927-9. Erratum in: *J Transl Med*. 2025 Jan 8;23(1):28. doi: 10.1186/s12967-024-05971-5.

14. López RI, Castro JL, Cedeño H, Cisneros D, Corrales L, González-Herrera I, et al. Consensus on management of metastatic colorectal cancer in Central America and the Caribbean: San José, Costa Rica, August 2016. *ESMO Open*. 2018 Mar 15;3(3):e000315. doi: 10.1136/esmoopen-2017-000315.

15. Quesada-Soto P, Landaverde D, Ramos-Esquivel A. Liver metastasectomy and systemic therapy improve overall survival compared with surgery alone after curative liver resection of colorectal metastases in a developing country (Costa Rica). *J Glob Oncol*. 2016 May 4;3(1):31-6. doi: 10.1200/JGO.2016.003285.

16. Nunes Filho PRS, et al. Latin America and cancer clinical trials: Underrepresented region with significant growth potential. *JCO*. 2024;42:e23038-e23038. doi: 10.1200/JCO.2024.42.16_suppl.e23038.
17. Jácome AA, Mathias-Machado MC, Gil M, Passarini TM, Cristofaro S, Moraes ED, et al. Later lines of systemic therapy in patients with metastatic colorectal cancer: real-world data from a setting with barriers to access cancer therapies. *J Gastrointest Oncol*. 2024 Dec 31;15(6):2543-51. doi: 10.21037/jgo-24-524. Epub 2024 Dec 28.
18. Catani G, Kim S, Waisberg F, Enrico D, Luca R, Estes F, et al. Patients with colorectal cancer and BRAFV600E-mutation in Argentina: A real-world study-The EMOGI-CRC01 study. *Cancers (Basel)*. 2025;17(6):1007. doi: 10.3390/cancers17061007.
19. O'Connor J, Torrecillas L, Alvarado F, Colombero C, Sasse A. Biomarkers and treatment characteristics in metastatic colorectal cancer RASwt patients in Latin America. *Gac Mex Oncol*. 2023;22(1):24-33. Epub 2023 Jun 12. doi: 10.24875/j.gamo.22000074.
20. White C, Scott RJ, Paul C, Ziolkowski A, Mossman D, Ackland S. Ethnic diversity of DPD activity and the DPYD gene: review of the literature. *Pharmgenomics Pers Med*. 2021 Dec 9;14:1603-17. doi: 10.2147/PGPM.S337147.
21. Montalvan-Sanchez EE, Norwood DA, Dougherty M, Beas R, Guranizo-Ortiz M, Ramirez-Rojas M, et al. Colorectal cancer screening programs in Latin America: a systematic review and meta-analysis. *JAMA Netw Open*. 2024 Feb 5;7(2):e2354256. doi: 10.1001/jamanetworkopen.2023.54256.
22. Unger-Saldaña K, Saldaña-Tellez M, Potter MB, Van Loon K, Allen-Leigh B, Lajous M. Barriers and facilitators for colorectal cancer screening in a low-income urban community in Mexico City. *Implement Sci Commun*. 2020 Jul 10;1:64. doi: 10.1186/s43058-020-00055-z.
23. Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, et al. *Global Cancer Observatory: Cancer Today*. Lyon, France: International Agency for Research on Cancer; 2024. Available from: <https://gco.iarc.who.int/today>.
24. Reich M, Buki LP. Colorectal cancer screening in Uruguay: current assessment and roadmap for the future. *Psicol Reflex Crit*. 2021 Jun 29;34(1):20. doi: 10.1186/s41155-021-00178-9.
25. Colón-López V, Valencia-Torres IM, Ríos EI, Llavona J, Vélez-Álamo C, Fernández ME. Knowledge, attitudes, and beliefs about colorectal cancer screening in Puerto Rico. *J Cancer Educ*. 2023 Apr;38(2):552-61. doi: 10.1007/s13187-022-02153-z. Epub 2022 Mar 31.
26. Fleitas-Kanonnikoff T, Martinez-Ciarpaglini C, Ayala J, et al. Molecular profile in Paraguayan colorectal cancer patients, towards a precision medicine strategy. *Cancer Med*. 2019 Jun;8(6):3120-30. doi: 10.1002/cam4.2191.
27. Lima Pérez M, Galán Álvarez YH, Soriano García JL, Iglesias Ventura Y, Medina Pérez VM. Incidence and mortality of gastrointestinal cancer in Cuba, 2015-2017. *Rev Cubana Oncol*. 2021 May-Aug;19(2):e_142.
28. Mondschein S, Subiabre F, Yankovic N, Estay C, Von Mühlenbrock C, Berger Z. Colorectal cancer trends in Chile: A Latin-American country with marked socioeconomic inequities. *PLoS One*. 2022 Nov 10;17(11):e0271929. doi: 10.1371/journal.pone.0271929.
29. Campo-Sánchez SM, Camargo-Trillos J, Calle-Ramírez JA, Gómez-Wolff LR, Sánchez-Patiño LA, García-García HI. Colorectal cancer survival at an oncologic center in Colombia: A historic cohort study. *Rev Gastroenterol Mex (Engl Ed)*. 2019 Apr-Jun;84(2):174-84. doi: 10.1016/j.rgmx.2018.04.002. Epub 2018 Jun 6.
30. Politis M, Higuera G, Chang LR, Gomez B, Bares J, Motta J. Trend analysis of cancer mortality and incidence in Panama, using Joinpoint regression analysis. *Medicine (Baltimore)*. 2015 Jun;94(24):e970. doi: 10.1097/MD.0000000000000970.
31. Dantas AAG, de Oliveira NPD, Costa GAB, Martins LFL, Dos Santos JEM, Migowski A, et al. Multilevel analysis of social determinants of advanced stage colorectal cancer diagnosis. *Sci Rep*. 2024 Apr 26;14(1):9667. doi: 10.1038/s41598-024-60449-0. Erratum in: *Sci Rep*. 2024 Jul 8;14(1):15718. doi: 10.1038/s41598-024-66240-5.
32. Ramos-Esquível A, Garita-Rojas E, Masís-Marroquín A. Determinantes de supervivencia en una cohorte de pacientes costarricenses con cáncer colorrectal. *Acta Méd Costarric*. 2022;64(2):16-23. Epub 2022 Jun 1. doi: 10.51481/amc.v64i2.1183.
33. Caramutti-Pasco BA, Oyola-García AE, Quispe-Illanzo MP. Caracterización clínica y colonoscópica del adenocarcinoma colorrectal en un hospital peruano de la seguridad social. *Rev Cuerpo Med HNAAA*. 2017;10(4). doi: 10.35434/rcmhnaaa.2017.104.20.
34. Cueva P, Tarupi W, Caballero H. Cancer incidence and mortality in Quito: information to monitor cancer control policies. *Colomb Med (Cali)*. 2022 Feb 9;53(1):e2024929. doi: 10.25100/cm.v53i1.4929.
35. Lozano-Esparza S, Sánchez-Blas HR, Huitzil-Meléndez FD, Meneses-Medina MI, Van Loon K, Potter MB, et al. Colorectal cancer survival in Mexico: Leveraging a national health insurance database. *Cancer Epidemiol*. 2025 Feb;94:102698. doi: 10.1016/j.canep.2024.102698. Epub 2024 Nov 21.